Y-mAbs Therapeutics, Inc. Research and Development Expense
Y-mAbs Therapeutics, Inc. reported Research and Development Expense of $11.10 million for the 3-month period ending 2025-06-30, per its 10-Q filed 2025-08-08.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:ResearchAndDevelopmentExpense · last filed 2025-08-08
- Y-mAbs Therapeutics, Inc. research and development expense for the quarter ending 2025-06-30 was $11.10M, a 10.02% decline year-over-year.
- Y-mAbs Therapeutics, Inc. research and development expense for the quarter ending 2025-03-31 was $11.36M, a 14.38% decline year-over-year.
- Y-mAbs Therapeutics, Inc. research and development expense for the quarter ending 2024-12-31 was $12.21M, a 8.77% decline year-over-year.
- Y-mAbs Therapeutics, Inc. research and development expense for the quarter ending 2024-09-30 was $11.17M, a 27.28% decline year-over-year.
- Y-mAbs Therapeutics, Inc. research and development expense for fiscal 2024 was $48.99M, a 9.64% decline from fiscal 2023.
- Y-mAbs Therapeutics, Inc. research and development expense for fiscal 2023 was $54.22M, a 40.79% decline from fiscal 2022.
- Y-mAbs Therapeutics, Inc. research and development expense for fiscal 2022 was $91.57M, a 1.79% decline from fiscal 2021.
- Y-mAbs Therapeutics, Inc. research and development expense for fiscal 2021 was $93.25M, a 0.48% decline from fiscal 2020.
| Period end | Research and Development Expense 3 month | Research and Development Expense 6 month | Research and Development Expense 9 month | Research and Development Expense 12 month |
|---|---|---|---|---|
| 2025-06-30 | $11.10M 10-Q · filed 2025-08-08 | $22.46M 10-Q · filed 2025-08-08 | $34.68M derived: sum of 3 quarters · filed 2025-08-08 | $45.84M derived: sum of 4 quarters · filed 2025-08-08 |
| 2025-03-31 | $11.36M 10-Q · filed 2025-05-13 | $23.57M derived: sum of 2 quarters · filed 2025-05-13 | $34.74M derived: sum of 3 quarters · filed 2025-05-13 | $47.08M derived: sum of 4 quarters · filed 2025-08-08 |
| 2024-12-31 | $12.21M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-04 | $23.38M derived: sum of 2 quarters · filed 2025-03-04 | $35.72M derived: sum of 3 quarters · filed 2025-08-08 | $48.99M 10-K · filed 2025-03-04 |
| 2024-09-30 | $11.17M 10-Q · filed 2024-11-08 | $23.51M derived: sum of 2 quarters · filed 2025-08-08 | $36.78M 10-Q · filed 2024-11-08 | $50.16M derived: sum of 4 quarters · filed 2025-08-08 |
| 2024-06-30 | $12.34M 10-Q · filed 2025-08-08 | $25.61M 10-Q · filed 2025-08-08 | $39.00M derived: sum of 3 quarters · filed 2025-08-08 | $54.35M derived: sum of 4 quarters · filed 2025-08-08 |
| 2024-03-31 | $13.27M 10-Q · filed 2025-05-13 | $26.66M derived: sum of 2 quarters · filed 2025-05-13 | $42.01M derived: sum of 3 quarters · filed 2025-05-13 | $54.07M derived: sum of 4 quarters · filed 2025-05-13 |
| 2023-12-31 | $13.39M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-04 | $28.75M derived: sum of 2 quarters · filed 2025-03-04 | $40.80M derived: sum of 3 quarters · filed 2025-03-04 | $54.22M 10-K · filed 2025-03-04 |
| 2023-09-30 | $15.36M 10-Q · filed 2024-11-08 | $27.41M derived: sum of 2 quarters · filed 2024-11-08 | $40.83M 10-Q · filed 2024-11-08 | $60.62M derived: sum of 4 quarters · filed 2024-11-08 |
| 2023-06-30 | $12.05M 10-Q · filed 2024-08-12 | $25.47M 10-Q · filed 2024-08-12 | $45.26M derived: sum of 3 quarters · filed 2024-08-12 | $67.71M derived: sum of 4 quarters · filed 2024-08-12 |
| 2023-03-31 | $13.42M 10-Q · filed 2024-05-07 | $33.20M derived: sum of 2 quarters · filed 2024-05-07 | $55.66M derived: sum of 3 quarters · filed 2024-05-07 | $82.08M derived: sum of 4 quarters · filed 2024-05-07 |
| 2022-12-31 | $19.79M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-29 | $42.24M derived: sum of 2 quarters · filed 2024-02-29 | $68.66M derived: sum of 3 quarters · filed 2024-02-29 | $91.57M 10-K · filed 2024-02-29 |
| 2022-09-30 | $22.45M 10-Q · filed 2023-11-13 | $48.87M derived: sum of 2 quarters · filed 2023-11-13 | $71.78M 10-Q · filed 2023-11-13 | $100.54M derived: sum of 4 quarters · filed 2023-11-13 |
| 2022-06-30 | $26.42M 10-Q · filed 2023-08-10 | $49.33M 10-Q · filed 2023-08-10 | $78.09M derived: sum of 3 quarters · filed 2023-08-10 | $101.22M derived: sum of 4 quarters · filed 2023-08-10 |
| 2022-03-31 | $22.91M 10-Q · filed 2023-05-08 | $51.67M derived: sum of 2 quarters · filed 2023-05-08 | $74.80M derived: sum of 3 quarters · filed 2023-05-08 | $94.58M derived: sum of 4 quarters · filed 2023-05-08 |
| 2021-12-31 | $28.76M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-30 | $51.89M derived: sum of 2 quarters · filed 2023-03-30 | $71.67M derived: sum of 3 quarters · filed 2023-03-30 | $93.25M 10-K · filed 2023-03-30 |
| 2021-09-30 | $23.13M 10-Q · filed 2022-11-07 | $42.91M derived: sum of 2 quarters · filed 2022-11-07 | $64.49M 10-Q · filed 2022-11-07 | $88.50M derived: sum of 4 quarters · filed 2022-11-07 |
| 2021-06-30 | $19.78M 10-Q · filed 2022-08-08 | $41.36M 10-Q · filed 2022-08-08 | $65.37M derived: sum of 3 quarters · filed 2022-08-08 | $86.37M derived: sum of 4 quarters · filed 2022-08-08 |
| 2021-03-31 | $21.58M 10-Q · filed 2022-05-09 | $45.59M derived: sum of 2 quarters · filed 2022-05-09 | $66.59M derived: sum of 3 quarters · filed 2022-05-09 | $96.65M derived: sum of 4 quarters · filed 2022-05-09 |
| 2020-12-31 | $24.01M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-01 | $45.02M derived: sum of 2 quarters · filed 2022-03-01 | $75.08M derived: sum of 3 quarters · filed 2022-03-01 | $93.70M 10-K · filed 2022-03-01 |
| 2020-09-30 | $21.00M 10-Q · filed 2021-11-04 | $51.06M derived: sum of 2 quarters · filed 2021-11-04 | $69.69M 10-Q · filed 2021-11-04 | $86.51M derived: sum of 4 quarters · filed 2022-03-01 |
| 2020-06-30 | $30.06M 10-Q · filed 2021-08-09 | $48.68M 10-Q · filed 2021-08-09 | $65.51M derived: sum of 3 quarters · filed 2022-03-01 | $85.17M derived: sum of 4 quarters · filed 2022-03-01 |
| 2020-03-31 | $18.62M 10-Q · filed 2021-05-06 | $35.45M derived: sum of 2 quarters · filed 2022-03-01 | $55.11M derived: sum of 3 quarters · filed 2022-03-01 | $69.60M derived: sum of 4 quarters · filed 2022-03-01 |
| 2019-12-31 | $16.83M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-01 | $36.49M derived: sum of 2 quarters · filed 2022-03-01 | $50.98M derived: sum of 3 quarters · filed 2022-03-01 | $63.49M 10-K · filed 2022-03-01 |
| 2019-09-30 | $19.66M 10-Q · filed 2020-11-05 | $34.15M derived: sum of 2 quarters · filed 2020-11-05 | $46.66M 10-Q · filed 2020-11-05 | $57.71M derived: sum of 4 quarters · filed 2020-11-05 |
| 2019-06-30 | $14.49M 10-Q · filed 2020-08-06 | $27.00M 10-Q · filed 2020-08-06 | $38.05M derived: sum of 3 quarters · filed 2020-08-06 | $46.78M derived: sum of 4 quarters · filed 2020-08-06 |
| 2019-03-31 | $12.51M 10-Q · filed 2020-05-07 | $23.55M derived: sum of 2 quarters · filed 2020-05-07 | $32.28M derived: sum of 3 quarters · filed 2020-05-07 | $40.58M derived: sum of 4 quarters · filed 2020-05-07 |
| 2018-12-31 | $11.04M derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-12 | $19.77M derived: sum of 2 quarters · filed 2020-03-12 | $28.07M derived: sum of 3 quarters · filed 2020-03-12 | $34.27M 10-K · filed 2020-03-12 |
| 2018-09-30 | $8.73M 10-Q · filed 2019-11-13 | $17.02M derived: sum of 2 quarters · filed 2019-11-13 | $23.23M 10-Q · filed 2019-11-13 | $29.85M derived: sum of 4 quarters · filed 2019-11-13 |
| 2018-06-30 | $8.29M 10-Q · filed 2019-08-14 | $14.50M 10-Q · filed 2019-08-14 | $21.12M derived: sum of 3 quarters · filed 2019-08-14 | $24.20M derived: sum of 4 quarters · filed 2019-08-14 |
| 2018-03-31 | $6.20M 10-Q · filed 2019-05-10 | $12.83M derived: sum of 2 quarters · filed 2019-05-10 | $15.90M derived: sum of 3 quarters · filed 2019-05-10 | |
| 2017-12-31 | $6.63M derived: 10-K 12 month − 10-Q 9 month · filed 2019-03-22 | $9.70M derived: sum of 2 quarters · filed 2019-03-22 | $14.31M 10-K · filed 2019-03-22 | |
| 2017-09-30 | $3.08M 10-Q · filed 2018-11-13 | $7.68M 10-Q · filed 2018-11-13 |